logo
Share SHARE
FONT-SIZE Plus   Neg

Endo Pharma Files Amendment To Its Citizen Petition With FDA - Quick Facts

Endo Pharmaceuticals (ENDP) said it has filed an amendment to its Citizen Petition with the FDA calling on FDA to publicly address numerous concerns raised by Endo and other experts about approval requirements for generic versions of LIDODERM, or lidocaine patch 5%.

The amended Citizen Petition highlights the growing scientific and regulatory support for requiring generic manufacturers to conduct comparative clinical endpoint studies to demonstrate bioequivalence to locally acting topical products like LIDODERM. The amended Citizen Petition also raises several new issues that need to be resolved before FDA approves a generic formulation of LIDODERM.

The amended Citizen Petition asks FDA to address the repeated public statements by scientific experts and FDA officials that pharmacokinetic studies, which measure the level of a drug in the bloodstream, have not yet been validated as a bioequivalence method for locally acting topical drugs like LIDODERM.

The amendment also points out that FDA has not produced any evidence indicating that pharmacokinetic studies are sufficiently sensitive to determine whether a proposed generic product will replicate LIDODERM's clinical effect.

Ivan Gergel, Executive Vice President of R&D and Chief Scientific Officer at Endo, said, "..FDA must publicly address the many unanswered questions from the original petition, as well as the additional concerns raised in this amendment, before taking any formal steps toward the approval of a generic version of LIDODERM."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations. Google is planning to significantly expand a carpool service on its navigational app Waze, according to a report in the Wall Street Journal. The move indicates the company is edging closer to a potential clash with ride-hailing service Uber Technologies Inc.
comments powered by Disqus
Follow RTT